Feb 16 (Reuters) - Sarepta Therapeutics said on Friday that the U.S. FDA will not conduct a meeting of its advisers and will do a priority review for traditional approval of its gene therapy Elevidys for a muscle wasting disorder. (Reporting by Christy Santhosh)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
In addition to economic and earnings news, inflation and geopolitical worries will have roles to play.
The $50 million purchase could turn into Nvidia's biggest investment.
A month after a higher state minimum wage for fast-food workers went into effect, consumers picking up burgers and burritos at chains in the Golden State grapple with prices rising at a faster clip than in other states.
This little-known software stock could soar as businesses spend more on generative artificial intelligence.
These two dividend payers have historically high yields and attractive businesses, even though there are some headwinds to deal with.
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
SHANGHAI (Reuters) -Tesla CEO Elon Musk arrived in Beijing on Sunday for a surprise visit, where he is expected to meet senior officials to discuss the rollout of Full Self-Driving software and permission to transfer data overseas, according to a person with knowledge of the matter. The U.S. electric vehicle maker rolled out Full Self-Driving, or FSD, the most autonomous version of its Autopilot software, four years ago but has yet to make it available in China, its second-largest market globally, despite customers urging it to do so. Musk said this month Tesla may make FSD available to customers in China "very soon", in response to a query on social media platform X.
“When she died, we were told by her attorney that we were responsible for the taxes and property insurance during the time when the life tennant lives in the home.”
The tobacco giant will soon be allowed to sell a proven product in a proven market.